Northera Blue Flamingo
Medical Patient Icon

Identify appropriate patients

Northera Blue Flamingo
Medical Patient Icon

Identify appropriate patients

Symptomatic nOH is caused by autonomic failure1

Classic symptoms of nOH include orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out.”1,2

nOH is one of the various types of orthostatic hypotension (OH)3-5

Ruling out other causes of OH and orthostatic intolerance is an important step in identifying patients with nOH.2,3

Parkinson's disease (PD)

Multiple system atrophy (MSA)

Pure autonomic failure (PAF)

Non-diabetic autonomic neuropathy

Dopamine beta-hydroxylase deficiency





Other medications



Cardiac insufficiency

Impaired venous return

Headshot of Gail, a NORTHERA patient

Learn more about Gail, a real patient, and her journey with symptomatic nOH through a patient profile.

Symptomatic nOH is due to inadequate release of NE upon standing or changing positions6,7

  • In patients with PD, MSA, PAF, and non-diabetic autonomic neuropathy disorders, the autonomic nervous system may fail to release adequate amounts of NE upon standing or postural change6-8
    • nOH occurs with postural changes and is caused by an insufficient autonomic NE response that normally maintains blood pressure. In patients with nOH, there is little to no compensatory increase in heart rate with a drop in blood pressure.6,9,10
    • If the standing blood pressure decrease cannot sustain adequate cerebral perfusion, nOH may become symptomatic6,8-10
  • Inadequate release of NE may lead to impaired vasoconstriction and cerebral hypoperfusion, resulting in the classic nOH symptoms upon standing2,6,7,9,10:
    • Dizziness
    • Lightheadedness
    • The “feeling that you are about to black out”2,7
  • A retrospective study, which included 61 patients with nOH and 85 control subjects, evaluated whether supine hypertension was associated with OH in patients with primary chronic autonomic failure11
    • In addition to other observations, it was found that NE levels in the plasma after standing were lower in those patients with autonomic failure and OH compared to the control group11
    • Plasma NE was measured after at least 15 minutes of supine rest and after 5 minutes of standing upright11

NORTHERA® (droxidopa) is an NE prodrug1

Graph icon

NORTHERA clinical studies were specifically designed to study reductions in nOH symptoms.1,2


Titration icon

NORTHERA can be titrated to help patients achieve symptomatic relief.1,13


1. NORTHERA [package insert]. Deerfield, IL: Lundbeck. 2. Freeman R. N Engl J Med. 2008;358(6):615-624. 3. Goldstein DS, Sharabi Y. Circulation. 2009;119(1):139-146. 4. Bradley JG, Davis KA. Am Fam Physician. 2003;68(12):2393-2398. 5. Gibbons CH, Schmidt P, Biaggioni I, et al. J Neurol. 2017;264(8):1567-1582. 6. Freeman R, Wieling W, Axelrod FB, et al. Clin Auton Res. 2011;21(2):69-72. 7. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. Clin Auton Res. 2012;22(2):79-90. 8. Figueroa JJ, Basford JR, Low PA. Cleve Clin J Med. 2010;77(5):298-306. 9. Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Expert Rev Cardiovasc Ther. 2015;13(8):875-891. 10. Isaacson SH, Skettini J. Vasc Health Risk Manag. 2014;10:169-176. 11. Goldstein DS, Pechnik S, Holmes C, et al. Hypertension. 2003;42(2):136-142. 12. Isaacson SH. Am J Manag Care. 2015;21(suppl 13):s258-s268. 13. Data on file. Deerfield, IL: Lundbeck.

Please see Important Safety Information, including Boxed Warning for supine hypertension.

For more information, see the full Prescribing Information.

Indications and Usage

NORTHERA (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically.

Important Safety Information


Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA.


  • NORTHERA is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients.


  • Supine Hypertension: NORTHERA therapy may cause or exacerbate supine hypertension in patients with nOH, which may increase the risk of cardiovascular events if not well managed, particularly stroke.
  • Hyperpyrexia and Confusion: Cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported with NORTHERA use during post-marketing surveillance. Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes. The early diagnosis of this condition is important for the appropriate management of these patients.
  • Ischemic Heart Disease, Arrhythmias, and Congestive Heart Failure: NORTHERA therapy may exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure. Careful consideration should be given to this potential risk prior to initiating therapy.
  • Allergic Reactions: Hypersensitivity reactions, including anaphylaxis, angioedema, bronchospasm, urticaria, and rash have been reported in post-marketing experience, with some resulting in emergency treatment. If a hypersensitivity reaction occurs, discontinue the drug and initiate appropriate therapy.
  • This product contains FD&C Yellow No. 5 (tartrazine), which may also cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.


  • The most common adverse reactions (>5% and ≥3% difference compared to placebo) were headache, dizziness, nausea, and hypertension.


  • Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension.
  • Dopa-decarboxylase inhibitors may require dose adjustments for NORTHERA.
  • The concomitant use of selective MAO-B inhibitors, such as rasagiline or selegiline, was permitted in the NORTHERA clinical trials. However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA.


  • There are no available data on use of NORTHERA in pregnant women and risk of major birth defects or miscarriage. Because of the potential for serious adverse reactions, including reduced weight gain in breastfed infants, advise a woman not to breastfeed during treatment with NORTHERA.
  • The safety and effectiveness of NORTHERA in pediatric patients have not been established. No overall differences in safety or effectiveness were observed between patients aged 75 years and older and younger patients in clinical trials, but greater sensitivity of some older individuals cannot be ruled out.
  • Clinical experience with NORTHERA in patients with severe renal function impairment (GFR <30 mL/min) is limited; therefore, dosing recommendations cannot be provided for these patients.

For more information, please see the full Prescribing Information, including Boxed Warning for supine hypertension.